Abbott to Pay $384M to Settle Contaminated Infant Formula Allegations
ABT sits 26% above its 52-week low of $81.97 on light trading volume (0.2× avg).
Summary
Abbott has agreed to pay $384 million to resolve allegations related to contaminated infant formula, according to the U.S. Justice Department. The settlement amount is reported as $385 million in a Dow Jones Newswires fragment, while the original summary states $384 million. This follows the company's earlier $670 million settlement of preterm infant formula litigation in August, indicating ongoing legal exposure in this area. The specific amount for this settlement was not previously disclosed, making this new information for investors. The payment is material but manageable given Abbott's large market capitalization, though it adds to the cumulative legal costs from the formula issues. Investors will watch for any further regulatory actions or additional claims.
At the time of this announcement, ABT was trading at $103.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $178.9B. The 52-week trading range was $81.97 to $137.49. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.